ABX-002 TRβ Agonist Enters Phase 1: Novel Mechanism, No Clinical Proof, No Matched Precedent

Autobahn Initiates Phase 1 Trial for ABX-002 in MDD

Autobahn Therapeutics has initiated dosing in a Phase 1 clinical trial for ABX-002, a potent and selective brain-boosting thyroid receptor beta (TRβ) agonist. This trial evaluates ABX-002 as a potential adjunctive treatment for Major Depressive Disorder (MDD) patients who experience an inadequate response to their antidepressant, addressing a significant unmet need where up to 50% of patients face this challenge. The company is encouraged by preclinical data demonstrating ABX-002's ability to engage depression-relevant target tissues in the brain, building on a wealth of published literature highlighting the effective use of thyroid hormone in treating depression.

• Major Depressive Disorder (MDD) presents a significant unmet medical need, with up to 50% of patients experiencing an inadequate response to existing antidepressant therapies. Autobahn Therapeutics aims to address this by developing ABX-002 as a novel adjunctive treatment, leveraging the established benefits of thyroid hormone in depression, which is supported by extensive published literature and inclusion in most clinical treatment guidelines.
• ABX-002 is an orally administered, brain-enhanced, potent, and selective thyroid hormone receptor beta (TRβ) agonist. It is designed to demonstrate target engagement in brain regions associated with depression while exhibiting reduced peripheral liabilities compared to synthetic thyroid hormone T3. The drug is expected to augment antidepressant effects by potentiating beneficial monoaminergic signaling in the brain.
• The ongoing Phase 1 trial is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study, which also includes food effect and bridging pharmacokinetic (PK) assessments in healthy volunteers. Following the completion of the multiple-ascending dose portion, Autobahn plans to initiate an open-label Phase 1b patient cohort within the same study to further explore the safety and potential effects of ABX-002 in MDD patients with an inadequate response to their antidepressant.

Addressing the Inadequate Response in Major Depressive Disorder

Despite decades of pharmacological development, major depressive disorder remains a leading cause of global disability, with current treatment paradigms falling short for a substantial proportion of patients. The biological heterogeneity of MDD is not adequately captured by symptom-based diagnostic systems, and the dominant monoamine hypothesis does not fully account for variability in treatment response, delayed therapeutic onset, or the persistence of cognitive and anhedonic symptoms.

• Treatment-resistant depression remains a critical unmet need. Approximately 30% of patients with MDD do not respond sufficiently to established pharmacological, psychotherapeutic, or somatic treatments. The minority of patients — 25% in unipolar depression cohorts — report that their current treatment plan is completely effective, underscoring the scale of inadequate response in real-world practice.

• The trial-and-error nature of antidepressant selection limits precision and patient outcomes. Treatment of MDD often entails a trial-and-error process of finding a suitable antidepressant and its appropriate dose. No biomarkers have been confirmed as predictors of treatment response for tricyclic antidepressants, and biomarker studies are limited by small sample sizes, inconsistent endpoint definitions, and a lack of adequate replication studies.

• Delayed onset of action and incomplete symptom resolution persist across conventional agents. Monoaminergic agents such as SSRIs and TCAs demonstrate delayed therapeutic onset and do not adequately address cognitive dysfunction or anhedonia. Glutamatergic-neuroplastic impairment — including synaptic atrophy driven by alterations in BDNF-TrkB-mTOR pathways and glial function — represents a mechanistic dimension that conventional monoaminergic treatments do not directly engage.

• Patient-relevant tolerability outcomes drive discontinuation but are inadequately captured in clinical trials. Weight gain is the adverse effect most commonly leading patients to discontinue medication, with lethargy, emotional blunting, shaking/trembling, and anxiety also identified as common treatment-emergent experiences leading to discontinuation in greater than one-third of survey respondents. These patient-centred outcomes are inadequately assessed by current standard clinical trial outcome measures.

• Rapid-acting alternatives carry their own limitations. While ketamine and esketamine provide clinical proof-of-concept for direct engagement of synaptic plasticity mechanisms, their benefits are offset by a significantly shorter duration of antidepressant effects, accessibility limitations, and concerns around bladder toxicity and abuse potential — areas for which there remain insufficient long-term data.

• Neuromodulation approaches face evidence and equity gaps. Most patients with treatment-resistant depression face a trial-and-error approach to neuromodulation therapeutics due to reduced availability and lacking long-term efficacy data, contravening the ethical criteria of patient autonomy and justice.

ABX-002: A Brain-Enhanced TRβ Agonist for MDD

Research into MDD pathophysiology has moved well beyond monoaminergic mechanisms, with glutamatergic signaling emerging as one of the most clinically validated novel targets. All currently approved antidepressants act primarily through monoaminergic pathways, yet remission rates are often less than 60% and onset of effect is delayed. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, whose rapid and robust antidepressant effects were first observed in 2000, has demonstrated the most promise among glutamatergic agents. Subsequent investigation has extended to non-competitive NMDA antagonists (memantine, dextromethorphan, AZD6765), subunit-specific GluN2B antagonists (CP-101,606/traxoprodil, MK-0657), glycine-site partial agonists (GLYX-13, D-cycloserine), and metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant). Additional preclinical targets under evaluation include AMPA receptor agonists and mGluR2/3 negative allosteric modulators, as well as mGluR7 agonists.

Neuroplasticity-focused mechanisms represent a second major frontier. Sirtuin 1 has been identified as a regulator of dendritic outgrowth and spine formation through mTORC1 signaling, with the selective sirtuin 1 activator SRT2104 significantly increasing phosphorylation of mTORC1 and its downstream targets 4E-BP1 and p70S6K, and augmenting dendritic outgrowth and spine density in dexamethasone-treated rat primary cortical cells. Separately, the 14-3-3ζ/GSK-3β/CREB/BDNF signaling pathway has been implicated in neuroplasticity restoration, with the traditional formula Zhi-Zi-Chi-Tang demonstrating antidepressant-like effects in a chronic unpredictable mild stress model through promotion of 14-3-3ζ binding to p-GSK-3β (Ser9) and upregulation of hippocampal BDNF. Immune-mediated disruption of neuroplasticity — including IFN-α- and TLR3-driven reductions in apical dendritic spine density and TrkB signaling in hippocampal CA1 — further underscores synaptic structural integrity as a tractable therapeutic axis.

Neuroinflammation and the endocannabinoid system (ECS) constitute additional emerging target domains. Microglial activation, characterized by pro-inflammatory M1 polarization, increased cytokine release, and oxidative stress, is increasingly recognized as central to MDD pathogenesis. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants have all been shown to attenuate microglial activation in neuroinflammation models, though results for agents such as bupropion, agomelatine, phenelzine, venlafaxine, and sertraline remain inconsistent. Nanotechnology-based delivery systems targeting microglia are under preclinical investigation as a means to enhance BBB penetration and promote a shift from M1 to M2 microglial phenotype. Within the ECS, CB1 and CB2 receptors and the enzymes governing anandamide and 2-arachidonoylglycerol metabolism are being explored as anxiolytic and antidepressant targets, with inhibitors of anandamide hydrolysis having reached early clinical safety evaluation, though tolerance and effects on learning and memory remain concerns for irreversible monoacylglycerol lipase inhibitors.

Unpacking the Phase 1 Trial Design for ABX-002 in MDD

Several key trials across pharmacological and non-pharmacological interventions have evaluated study designs and endpoints in MDD, spanning acute treatment, relapse prevention, and maintenance phases.

Unlocking Brain-Specific Thyroid Action for Refractory Depression

The initiation of a Phase 1 trial for ABX-002 marks a pivotal moment in the ongoing quest to provide more effective treatments for Major Depressive Disorder (MDD), particularly for the substantial patient population that experiences an inadequate response to conventional antidepressants. This novel compound, a selective brain-boosting thyroid receptor beta (TRβ) agonist, seeks to harness the well-documented benefits of thyroid hormone in depression while addressing the limitations of earlier approaches.

Existing literature has consistently shown that augmentation with liothyronine (T3) can significantly enhance the antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), leading to improved response and remission rates. However, the broader application of non-selective thyroid hormone has been constrained by concerns regarding systemic side effects, notably those impacting cardiac function, which are largely mediated by thyroid receptor alpha (TRα).

ABX-002's strategic focus on TRβ agonism, particularly with a 'brain-boosting' intent, aims to circumvent these systemic challenges. Research indicates TRβ's critical role in neurodevelopment and its expression in brain regions, suggesting a direct pathway for therapeutic action in MDD. By selectively targeting TRβ, the drug aims to maximize central nervous system benefits while minimizing the risks associated with TRα activation in peripheral tissues like the heart.

However, several considerations will be paramount as ABX-002 progresses through clinical development. The true extent of its selectivity for TRβ over TRα in humans, and its ability to consistently achieve therapeutically relevant brain penetration and engagement, will be crucial. Furthermore, its efficacy and safety profile will need to demonstrate a clear advantage over established augmentation strategies for treatment-resistant depression, such as liothyronine or lithium, which, despite their monitoring requirements, have proven benefits. If successful, ABX-002 could offer a much-needed, targeted, and potentially safer adjunctive therapy, fundamentally improving outcomes for patients with refractory MDD.